Bourlond A, Lachapelle J M, Aussems J, Boyden B, Campaert H, Conincx S, Decroix J, Geeraerts C, Ghekiere L, Morias J
Department of Dermatology, Clinique University, Brussels, Belgium.
Int J Dermatol. 1989 Jul-Aug;28(6):410-2. doi: 10.1111/j.1365-4362.1989.tb02491.x.
Seventy-eight patients with tinea corporis or tinea cruris participated in a double-blind study with either 100 mg itraconazole or 500 mg ultramicronized griseofulvin for 15 consecutive days. Clinical outcome was significantly in favor of itraconazole at completion of treatment (72% response rate vs. 51%) and at the follow-up visit (91% response vs. 64%). The most important difference between both treatments was the mycologic outcome, for which itraconazole showed a cure rate of 87% compared to 57% for griseofulvin 2 weeks after completion of therapy. It is suggested that 100 mg of itraconazole orally once daily is significantly more effective than 500 mg of griseofulvin once daily for 15 days in the treatment of glabrous skin infections. Both drugs were well tolerated.
78例体癣或股癣患者参与了一项双盲研究，连续15天服用100毫克伊曲康唑或500毫克超微粉化灰黄霉素。治疗结束时，临床疗效显著有利于伊曲康唑（有效率72%对51%），随访时也是如此（有效率91%对64%）。两种治疗方法最重要的差异在于真菌学疗效，治疗结束2周后，伊曲康唑的治愈率为87%，而灰黄霉素为57%。对于光滑皮肤感染的治疗，建议每日口服100毫克伊曲康唑，连续15天，比每日口服500毫克灰黄霉素显著更有效。两种药物耐受性均良好。
